A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer

Background Inhibition of the programmed cell death protein 1 (PD‐1) pathway has demonstrated clinical benefit in metastatic urothelial cancer (mUC); however, response rates of 15% to 26% highlight the need for more effective therapies. Bruton tyrosine kinase (BTK) inhibition may suppress myeloid‐der...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer Vol. 126; no. 20; pp. 4485 - 4497
Main Authors:	Zhang, Tian, Harrison, Michael R., O'Donnell, Peter H., Alva, Ajjai S., Hahn, Noah M., Appleman, Leonard J., Cetnar, Jeremy, Burke, John M., Fleming, Mark T., Milowsky, Matthew I., Mortazavi, Amir, Shore, Neal, Sonpavde, Guru P., Schmidt, Emmett V., Bitman, Bojena, Munugalavadla, Veerendra, Izumi, Raquel, Patel, Priti, Staats, Janet, Chan, Cliburn, Weinhold, Kent J., George, Daniel J.
Format:	Journal Article
Language:	English
Published:	United States Wiley Subscription Services, Inc 15.10.2020 John Wiley and Sons Inc
Subjects:	Alanine Alanine transaminase Anemia Apoptosis Bladder cancer Bruton's tyrosine kinase Cancer CD8 antigen Cell activation Cell death Correlation analysis Immune system Immunotherapy Kinases Lymphocytes Lymphocytes T Metastases Metastasis Monoclonal antibodies Monocytes Oncology Original Patients Pembrolizumab Platinum programmed cell death receptor 1 protein kinase inhibitor Protein-tyrosine kinase Solid tumors Suppressor cells Survival Targeted cancer therapy Tumors Tyrosine Urinary tract urologic neoplasms Urothelial cancer Urothelial carcinoma protein kinase inhibitor programmed cell death receptor 1 immunotherapy urologic neoplasms
ISSN:	0008-543X, 1097-0142, 1097-0142
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!